DavidPaulRichmanMD

Professor, Neurology, UC, Davis School of Medicine

Dr. Richman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3160 Folsom Boulevard
UC Davis Department Of Neurology
Sacramento, CA 95816
Phone+1 916-734-3588

Fax+1 916-734-7188

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1971 - 1975
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1969 - 1971
Johns Hopkins University School of MedicineClass of 1969

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Whos Who in Medicine and Healthcare Marquis Whos Who

PubMed

390 citations
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-bli...
James F. Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn
The Lancet. Neurology. 2017-12-01
108 citations
A genome-wide association study of myasthenia gravis.
Alan E. Renton, Hannah A. Pliner, Carlo Provenzano, Amelia Evoli, Roberta Ricciardi
JAMA Neurology. 2015-04-01
48 citations
Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells.
Sangwook Oh, Xuming Mao, Silvio Manfredo-Vieira, Jinmin Lee, Darshil Patel
Nature Biotechnology. 2023-09-01

Development Of Animal Models Of Anti-Musk MyastheniaNational Institute Of Neurological Disorders And Stroke2010–2011
IX International Conference On Myasthenia GravisNational Institute Of Neurological Disorders And Stroke1997
Pathogenic Mechanisms In MyastheniaNational Institute Of Neurological Disorders And Stroke1994–1996
Antiidiotypic Antibodies In MyastheniaNational Institute Of Neurological Disorders And Stroke1994–1995
Anti-Idiotypic Antibodies In MyastheniaNational Institute Of Neurological Disorders And Stroke1991–1993
Pathogenic Mechanisms In Myasthenia GravisNational Institute Of Neurological Disorders And Stroke1991–1992
In Vivo Effects Of Antibodies Blocking Achr Function IonNational Institute Of Neurological Disorders And Stroke1991
Core--ScientificNational Institute Of Neurological Disorders And Stroke1991
Anti-Idiotypic Antibodies In MyastheniaNational Institute Of Neurological Disorders And Stroke1985–1991
Scientific CoreNational Institute Of Neurological Disorders And Stroke1989–1990
Structure/Function Analysis Of Acchr EpitopesNational Institute Of Neurological Disorders And Stroke1987–1990
In Vivo Effects Of Antibodies Blocking Acchr Function IonNational Institute Of Neurological Disorders And Stroke1987–1990
Pathogenic Mechanisms In Myasthenia GravisNational Institute Of Neurological Disorders And Stroke1985–1990